Dwight Technologies Private Limited acquired a 5.41% stake in Vivo Bio Tech Limited through an off-market transaction on August 21, 2026.

The Hyderabad-based acquirer purchased 12,00,000 equity shares, bringing its total holding to 30,72,561 shares. This represents 13.85% of the company’s total voting capital and 10.48% of its diluted share capital.

Acquisition Details

The transaction was reported under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Dwight Technologies confirmed it does not belong to the promoter or promoter group of Vivo Bio Tech.

The equity share capital of Vivo Bio Tech remained unchanged at 2,21,90,628 shares, aggregating ₹22,19,06,280. The total diluted share capital stands at 2,93,23,111 shares, based on the assumption that pending convertible equity warrants and outstanding ESOPs will be exercised.

What the Numbers Show

The acquisition significantly consolidates Dwight Technologies’ position as a major shareholder. By increasing its stake from 8.44% to 13.85%, the entity has crossed the 10% threshold in voting capital, which often triggers additional disclosure obligations and signals a deeper strategic interest in the target company’s governance and direction.

Vivo Bio Tech disclosed that its promoter group entity, P.K.L Solution Private Limited, transferred 6,00,000 equity shares off-market on August 21, 2026. The transaction reduced the entity’s stake in the company from 2.70% to nil.

The disclosure was filed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Jaivardhan Prasadam, Director of P.K.L Solution Private Limited (DIN: 00097958), signed the intimation submitted to BSE Limited.

Transaction Details

P.K.L Solution Private Limited held 6,00,000 equity shares prior to the transfer, representing 2.70% of the total share capital and 2.05% of the diluted share capital. The entire holding was disposed of in this single off-market transaction.

Capital Structure Context

The total equity share capital of Vivo Bio Tech remains unchanged at 2,21,90,628 equity shares of ₹10 each, aggregating ₹22,19,06,280. The diluted share capital stands at 2,93,23,111 equity shares, based on the assumption that pending convertible equity warrants and outstanding ESOPs will be exercised.

The pending instruments include:

• 6,27,409 convertible equity warrants
• 63,22,000 outstanding ESOPs

These instruments are assumed to be converted or exercised in one or more tranches for the purpose of calculating diluted voting capital.